GlaxoSmithKline (Ireland) Ltd.

Primary objectives: To evaluate the effectiveness of belimumab + standard therapy compared with placebo + standard therapy in slowing the decline in lung volume in CTD-ILD subjects. Key secondary objectives: To evaluate the effectiveness of belimumab + standard therapy compared with placebo + standard therapy in slowing the % predicted decline in lung volume in CTD-ILD subjects. To evaluate the effectiveness of belimumab + standard therapy compared with placebo + standard therapy in slowing the progression of ILD in CTD-ILD subjects. To evaluate the effect of belimumab + standard therapy compared with placebo + standard therapy on fatigue in CTD-ILD subjects. To evaluate the effect of belimumab + standard therapy compared with placebo + standard therapy in reducing the severity of symptoms in CTD-ILD subjects.

Primary objective: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the decline of lung volume in DCSSC-ILD subjects Key secondary objectives: To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing the degree of skin thickening at week 52 in DCSSC-ILD subjects To evaluate the effectiveness of belimumab compared with placebo on standard treatment in reducing fatigue in DCSSC-ILD subjects. To evaluate the effectiveness of belimumab compared with placebo on standard treatment in slowing the progression of SSC or reducing mortality in DCSSC-ILD subjects

1) Primary objective (pharmacokinetics): To evaluate the exposure of belimumab after administration of 200 mg SC belimumab in Chinese pediatric SLE subjects who had previously received belimumab IV treatment; 2) Secondary objective (safety): To evaluate the safety and tolerability of 200 mg SC belimumab in pediatric SLE subjects who had previously received belimumab IV treatment.